(Durvalumab)Biosimilar Reference Antibody-GS40198主打

货号：GS40198

Durvalumab is a fully human monoclonal antibody used as an immune checkpoint inhibitor for the treatment of cancer. Marketed under the brand name Imfinzi®, it is approved for multiple indications, including unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy, extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy, and locally advanced or metastatic biliary tract cancer (in combination with chemotherapy). It works by blocking the interaction between a key immune checkpoint protein and its receptors, thereby restoring anti-tumor T-cell activity.